Intervention Development for Social Stress, Mental Health, and HIV Risk MSM (ESTEEM)

May 14, 2015 updated by: Yale University

Intervention Development for Social Stress, Mental Health, and HIV Risk Among MSM

The proposed study will adapt a cognitive behavioral intervention to support high-risk MSM's adaptive coping with minority stress, alleviate associated depression and anxiety, and reduce HIV risk behavior. The adapted intervention is expected to increase awareness of the unhealthy impact of minority stress; facilitate objective self-schemas in the face of minority stress; and strengthen one's skills and self-efficacy for managing minority stress and associated anxiety and depression to reduce risk for acquiring HIV.

Study Overview

Status

Completed

Intervention / Treatment

Detailed Description

Gay, bisexual, and other men who have sex with men (MSM) are the population most severely affected by HIV in the U.S. and one of the only risk groups in the U.S. for which new infections continue to rise. MSM also experience a vastly disproportionate risk of mental health disorders, especially depression and anxiety. Numerous studies have shown that this mental health disparity arises from the early and ongoing stressors, known as minority stress, that MSM experience related to their sexual orientation. Despite the fact that minority stress is strongly related to anxiety and depression, and that minority stress and related mental health problems synergistically propel HIV risk behaviors, no existing HIV prevention intervention targets minority stress in order to reduce MSM's HIV risk behavior. This project aims to develop a theoretically-driven intervention that reduces the health-depleting effects of minority stress through targeting the basic psychosocial mechanisms linking minority stress to HIV risk behavior. These mechanisms include maladaptive emotion regulation, negative thinking styles, low self-efficacy, avoidance, and impulsivity, which are the very targets of an existing cognitive-behavioral, manualized intervention--the Unified Protocol for the Transdiagnostic Treatment of Emotional Disorders (UPTTED). The UPTTED changes these mechanisms using motivational interviewing, interoceptive and situational exposure, cognitive restructuring, mindfulness, and self-monitoring exercises, all grounded in cognitive-behavioral principles and developmental and affective neuroscience models of stress. The proposed study will adapt the UPTTED to support high-risk MSM's adaptive coping with minority stress, alleviate associated depression and anxiety, and reduce HIV risk behavior. The adapted UPTTED is expected to increase awareness of the unhealthy impact of minority stress; facilitate objective self-schemas in the face of minority stress; and strengthen one's skills and self-efficacy for managing minority stress and associated anxiety and depression to reduce risk for acquiring HIV. MSM who have experienced minority stress, mental health problems, and HIV risk behavior in the previous 3 months (n = 30) and community health experts (n = 30) will provide suggestions for adaptations to the existing intervention manual, including culturally relevant vignettes, examples, and exercises for adaptively responding to minority stress and managing HIV risk. The feasibility, acceptability, and preliminary efficacy of the adapted intervention will then be tested in a randomized waitlist controlled trial with MSM (n = 60) who report recent experiences with minority stress, depression and anxiety, and HIV risk behavior. The primary outcome will be HIV risk behavior. Secondary outcomes will be reductions in mediators including depression, anxiety, and the mechanisms of the conceptual model. This project innovatively seeks to test the preliminary efficacy of the first theoretically-driven intervention targeting the mental and sexual health consequences of minority stress and does so by targeting the underlying mechanisms that powerfully drive these simultaneous health threats.

Study Type

Interventional

Enrollment (Actual)

63

Phase

  • Not Applicable

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 35 years (Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

Male

Description

Inclusion Criteria:

  1. Subjective stress related to sexual identity over the previous three months;
  2. Symptoms of depression or anxiety within the past three months;
  3. HIV sexual risk behavior (one or more acts of condomless insertive or receptive anal sex with a male partner of unknown or discordant serostatus) within the past three months;
  4. Biological male gender;
  5. At least 18 years of age;
  6. Not known to have HIV;
  7. Residential stability and availability for six months;
  8. Ability to communicate in English; and
  9. Provision of informed consent.

Exclusion Criteria:

  1. active, unmedicated symptoms of bipolar I or bipolar II disorder or any Diagnostic and Statistical Manual-IV psychotic disorder in the past 12 months;
  2. Current suicidal or homicidal ideation;
  3. Evidence of gross cognitive impairment;
  4. Current enrollment in an HIV-related intervention or research study; and
  5. Knowledge of being infected with HIV.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Prevention
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: ESTEEM
cognitive behavioral treatment adapted to improve depression, anxiety, and co-occurring health risks (i.e., alcohol use, sexual compulsivity, condomless sex) among young adult gay and bisexual men by reducing minority stress processes that underlie sexual orientation-related mental health disparities
10-session cognitive behavioral treatment
No Intervention: Waitlist
3-month waitlist control

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
reductions in the number of condomless anal sex acts in the past 90 days with HIV-positive or HIV-status-unknown male partners
Time Frame: 3 months
3 months

Secondary Outcome Measures

Outcome Measure
Time Frame
reduction in depression severity as measured with the Center for Epidemiological Studies Depression Scale
Time Frame: 3 months
3 months
reduction in anxiety severity as measured with the Overall Anxiety Severity & Impairment Scale
Time Frame: 3 months
3 months
reduction in minority stressors as measured with the Sexual Orientation Concealment Scale
Time Frame: 3 months
3 months
reductions in psychological risk factors measured with the Ruminative Responses Scale
Time Frame: 3 months
3 months
reductions in number of days in which heavy alcohol and potentially harmful recreational substances were use
Time Frame: 3 months
3 months
among individuals with body image disturbance, improvements in body attitudes as measured with the Male Body Attitude Scale
Time Frame: 3 months
3 months
among individuals with sexual compulsivity, reduction in sexual compulsivity severity as measured with the Sexual Compulsivity Scale
Time Frame: 3 months
3 months
reduction in alcohol use problems as assessed with the Alcohol Use Disorders Identification Test
Time Frame: 3 months
3 months
in participants with generalized anxiety disorder, reduction in Penn State Worry Questionnaire
Time Frame: 3 months
3 months
reduction in depression severity as measured with the Overall Depression Severity & Impairment Scale
Time Frame: 3 months
3 months
reduction in anxiety severity as measured with the State Trait Anxiety Inventory (State subscale)
Time Frame: 3 months
3 months
reduction in minority stressors as measured with the Internalized Homophobia Scale
Time Frame: 3 months
3 months
reduction in minority stressors as measured with the Rejection Sensitivity Scale
Time Frame: 3 months
3 months
reductions in psychological risk factors measured with the Rathus Assertiveness Schedule
Time Frame: 3 months
3 months
reductions in psychological risk factors measured with the Difficulties of Emotion Regulation Scale
Time Frame: 3 months
3 months
reductions in psychological risk factors measured with the Multidimensional Scale of Perceived Social Support
Time Frame: 3 months
3 months
in participants with obsessive-compulsive disorder, reductions in the Yale-Brown OC Scale
Time Frame: 3 months
3 months
in participants with panic disorder, reduction in the Panic Disorder Severity Scale
Time Frame: 3 months
3 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

July 1, 2012

Primary Completion (Actual)

December 1, 2014

Study Completion (Actual)

December 1, 2014

Study Registration Dates

First Submitted

April 15, 2015

First Submitted That Met QC Criteria

May 14, 2015

First Posted (Estimate)

May 19, 2015

Study Record Updates

Last Update Posted (Estimate)

May 19, 2015

Last Update Submitted That Met QC Criteria

May 14, 2015

Last Verified

May 1, 2015

More Information

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Depression

Clinical Trials on ESTEEM

Subscribe